Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients.
Jindal
R M
RM
Mount Sinai Medical Center, Division of Liver Transplantation, New York, New York.
Popescu
I
I
Schwartz
M E
ME
Emre
S
S
Boccagni
P
P
Miller
C M
CM
D000328:Adult; D001161:Arteriosclerosis / Q000453:epidemiology / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005951:Glucose Tolerance Test; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D016572:Cyclosporine; D016559:Tacrolimus